Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › CGEN

Compugen

CGEN Lead: Phase 3 ★ Read the deep dive → 1 Biotech Distilled article ↓ 13 filings & releases ↓ Cash $90.6M (Dec 31, 2025) ↓ 1 verdict ↓ 1 timing quote ↓
Oncology Protein

Market cap $186M 94.7M shares (vendor count, Nov 7, 2026) × $1.96 close Nov 6, 2026 · share count from the market-data vendor, not the SEC cover page

Most recent annual filing: 2026-03-02

Catalyst timeline

4 trackedQuarter catalyst calendar →
  1. Rilvegostomig HER2 readout2026Rilvegostomig HER2 readout, 2026, notable
  2. Rilvegostomig ARTEMIDE-01 readout2H 2026Rilvegostomig ARTEMIDE-01 readout, 2H 2026, notable
  3. GS-0321 Ph1 interimLate 2026 / 2027GS-0321 Ph1 interim, Late 2026 / 2027, notable
  4. COM701 interim1Q 2027COM701 interim, 1Q 2027, major

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (7 active programs)

Technology platforms

Unigen

AI/ML powered computational drug target discovery platform using multi-omics datasets, genomics, single-cell RNA sequencing, proteomics and spatial transcriptomics to identify novel immuno-oncology drug targets for cancer immunotherapy

Capital (as filed)

Cash
$90.6M cash and cash equivalents · Dec 31, 2025 (20-F)
Short-term investments
$45.8M Dec 31, 2025
Operating cash flow
$7.9M annual ÷ 4, year to Dec 31, 2025 (20-F)
As stated in coverage
$135M cash, runway 2029 per the deep dive of Jun 3, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (1)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (1 call)

Every verdict Biotech Distilled has published on Compugen, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-06-04 Watch Compugen Ltd (CGEN) — Scientific Deep Dive for COM701, GS-0321 and the Unigen Pipeline Near-cash EV with partnered Phase 3 royalty and Gilead option provides cushion, but the owned binary (COM701 monotherapy maintenance) rests on a post-hoc subgroup and thin single-agent data in a distrusted checkpoint class, warranting a watch rather than an immediate buy.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Timing, in the company's words (1 quote from 1 filing)

Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.

Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.

Filings & releases (13)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Aug 3, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)